Global Therapeutic Plasma Exchange Market is Likely to Grow at a CAGR Value of 7.10% By 2028

The global therapeutic plasma exchange market size was worth USD 1,528.40 million in 2021 and is estimated to grow to USD 2306.60 million by 2028, with a compound annual growth rate (CAGR) of approximately 7.10 percent over the forecast period. The report analyzes the therapeutic plasma exchange market's drivers, restraints/challenges, and their effect on the demands during the projection period. In addition, the report explores emerging opportunities in the therapeutic plasma exchange market.

The therapeutic plasma exchange (TPE) procedure includes the passage of the patient's blood through an apheresis machine. The filtered plasma is extracted and discarded with the reinfusion of red blood cells and a replacement fluid like plasma. To get rid of a disease-causing material that is swimming in the plasma, a blood exchange treatment separates and removes plasma from the blood.

The individual also receives a specified replenishment liquid along with the red blood cells, white blood cells, and platelets. A significant amount of blood containing toxins and other aberrant material is removed from the other components and replaced with fresh frozen blood (FFP), donor serum, or protein as replacement fluid. The separated blood is processed in plasma transfusion to remove aberrant elements using second membrane filtration or an adsorptive column. Therapy for neurologic, kidney, hematologic, and metabolic problems can sometimes involve drug plasma exchanges (TPE).

The American Society for Apheresis (ASFA) has standards that govern the indications for adopting therapeutic plasma exchange treatments as a line of treatment. The indications are divided into four categories, ranging from I to IV. For numerous neurological, renal, and hematological conditions such as chronic autoimmune neurological dysfunction polyneuropathy (CIDP), muscular dystrophy, Guillain-Barre syndrome, and thrombotic thrombocytopenic purpura  (TTP), Categories I and II represent TPE as the first or second line of treatment.

The expansion of the global therapeutic plasma exchange market is driven by a growth in the incidence of numerous autoimmune diseases global, a marked increase in the use of lipoprotein apheresis as a treatment for cardiovascular conditions such as coronary artery disease (CAD), hypercholesterolemic strokes, and atherosclerotic, as well as a recent surge in the number of cardiac deaths. The chronic disease prevalence and aging population will contribute to the global market expansion during the coming period. An increase in healthcare spending will further boost the global market growth. However, the global therapeutic plasma exchange market's expansion is constrained by a lack of knowledge and expensive procedures.

The global therapeutic plasma exchange market is segregated based on disease indication, end-users, and region. Based on disease indication, the market is segmented as neurological disorders, renal disorders, hematology disorders, metabolic disorders, and others. Among these, the neurological disorder segment led the market in 2021 and is expected to maintain its dominance throughout the forecast period. Based on end-users, the market is categorized as hospitals, specialty clinics, and ambulatory surgical centers. In 2021, the hospital's category dominated the global market.

The global therapeutic plasma exchange market is divided into geographic regions: North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. The Asia Pacific market is expected to rise at an accelerating rate during the forecast period.  The prevalence and incidence of neurological diseases are increasing in the elderly population, knowledge of the use of plasma exchange in the therapy of neurodegenerative disorders is rising, and key companies are increasing their R&D expenditures on new applications for therapeutic plasma exchange in the management of neurological disorders.

These factors are the main drivers of market growth along with the growing expanding healthcare infrastructure in nations like India, China, South Korea, and Malaysia. The dominance is caused by a surge in the frequency of numerous autoimmune conditions global, a sharp increase in the use of lipoprotein apheresis as a therapy for cardiovascular conditions such as coronary artery disease (CAD), hyperlipidemia strokes, and atherosclerosis, as well as a rise in the number of cardiac deaths in recent years.

Key players in the global therapeutic plasma exchange market include Asahi Kasei Corporation, Baxter International, Inc., Terumo Corporation, B. Braun Melungeon AG, Fresenius Kabir AG, Karasumi Laboratories, Inc., Haemon tics Corporation, Ceros Corporation, Hema care Corporation, and Medica S.p.A.

Recent Development:

• April 2020- Fresenius joined up with DaVita and other dialysis companies to support a bigger kidney care community in the United States.
• April 2020 Terumo BCT and Marker Therapeutics received the first device FDA emergency use authorization (EUA) to treat COVID-19 patients with acute respiratory failure.

Browse the full “Therapeutic Plasma Exchange Market By Diseases Indication (Neurological Disorders, Renal Disorders, Hematology Disorders, Metabolic Disorders, And Others), By End-Users (Hospitals, Specialty Clinics, and Ambulatory Surgical Centers), and By Region - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2022 – 2028.” Report at https://www.zionmarketresearch.com/report/therapeutic-plasma-exchange-market

Global Therapeutic Plasma Exchange Market is segmented as follows:

By Diseases Indication

• Neurological Disorders
• Renal Disorders
• Hematology Disorders

By End-Users

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:

Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com